Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Bristol Myers Squibb BMY announced data from three studies evaluating CD19-directed CAR T cell therapy Breyanzi (liso-cel) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-465830317-72a07789a32346fea9e7a03b136d0060-f0f6c5eb79a8488594a827a5dbc4d404-ee5cf1a13bf5410caf16dbe25a019d7f.jpg "A Guide to Reselling Toys at the Holidays for Extra Money")
:max_bytes(150000):strip_icc():format(jpeg)/appraiser-c1c881cd00af4d6c8af80c98613b4f74.jpg "Home Appraisal Checklist")
:max_bytes(150000):strip_icc():format(jpeg)/stock-market-crash-sell-off---trading-screen-in-red-104271845-565bca2f055c47558a2d17ec3563a4dd.jpg "What Caused Black Monday, the 1987 Stock Market Crash?")